Antibiotic treatment for septic shock is generally prescribed on an empirical basis using broad-spectrum antibiotics. Molecular diagnostic techniques can detect the presence of microbial DNA in blood within a few hours and facilitate early, targeted treatment. The aim of this study was to evaluate the economic impact of a real-time polymerase chain reaction technique, lightCycler SeptiFast (lSC), in patients with sepsis.
Severe sepsis and septic shock are frequent clinical conditions, with an incidence of between 200 to 300 cases/100,000 inhabitants per year [1] [2] [3] . Despite the changes in treatment introduced and incorporated into guidelines for good clinical practice in recent years, both conditions continue to be serious and often cause mortality in excess of 30%.
Traditionally, microbiological diagnosis of infection in septic patients has been based on phenotypic techniques such as blood cultures used to identify live bacteria. This implies a delay in positive identification until day three after culture sampling, while negative readings take up to five days. Such delays in identifying the causal pathogen hinders specific treatment and makes it necessary to resort to broad-spectrum antibiotic treatment, which often prove excessive in regards to the amount and duration of antibiotic administration 4 . Some studies have highlighted the implication of inadequate antimicrobial treatment in high mortality observed among patients with sepsis admitted to the intensive care unit (ICU) [5] [6] [7] .
In recent years, molecular diagnostic systems have become available for detecting microbial DNA, thereby allowing identification of the causal pathogen within only a few hours. In this sense, it improves that clinical outcome by reducing the inappropriate use of antibiotics, shortens hospital stay [8] [9] [10] and reduces economic costs 11 .
Unlike drug treatments, economic evaluation studies have not systematically accompanied the introduction of diagnostic tests in clinical practice 12 . However, institutions such as the National Intitute for Health and Clinical Excellence have recently recognised the need to implement centralised processes of economic evaluation of diagnostic tests 13 . The number of economic evaluations investigating laboratory diagnostic testing has increased real-time polymerase chain reaction microbiological diagnosis substantially with applications to diverse clinical areas 13 . To date, no previous studies have been performed to analyse the cost effectiveness of polymerase chain reaction (PCr) microbiological diagnosis. The aim of this study was to evaluate the economic impact of the use of real-time PCr techniques in patients diagnosed with severe sepsis and septic shock.
MATeriAl And MeTHodS
This retrospective observational cost-minimisation study was carried out in patients admitted to the ICU of Santiago de Compostela University Hospital, Spain, with a diagnosis of severe sepsis or septic shock. Cases were recruited between December 2005 and December 2006 following introduction of the lightCycler SeptiFast (lCS) sepsis molecular diagnostic technique in our centre.
The ethics committee of the participating institution approved the study and written consent was obtained from each patient or relative as reflected in previous publications 9 .
Severe sepsis is defined as sepsis associated with organ dysfunction or tissue hypoperfusion. Septic shock is understood to represent persisting sepsis-induced hypotension, despite adequate fluid replacement [14] [15] [16] . In all cases, the 2004 guidelines for the management of sepsis were followed 14 . In addition to conventional cultures (blood culture, tracheal aspirate, urine, surgical wounds, intravenous catheters etc.), a blood sample was reserved for the molecular diagnosis of each patient. The initial diagnosis and the infectious origin of sepsis were recorded in all cases. Severity upon admission was scored using the Acute Physiology and Chronic Health Evaluation (APACHe) ii and Sequential organ Failure Assessment (SoFA) scales. The stay in the iCu, hospital admission, 28-day and six-month mortality, and the economic cost of the clinical process were also evaluated.
This study used the LCS system from roche Molecular Systems (Mannheim, Germany), based on a real-time multiplex PCr assay capable of identifying the DNA of the organisms responsible for 80 to 90% of all cases of sepsis in ICUs [9] [10] [11] .
The lCS technique comprises an in-vitro nucleic amplification test for the detection and identification of bacterial and mycotic DNA corresponding to specified micro-organisms. The great advantage of this multiplex real-time PCr technique is that within six hours it is able to detect the presence of 25 of the most important pathogens (bacteria and fungi) causing sepsis and nosocomial infections. The micro-organisms covered by the technique account for 90% of all the infections diagnosed in blood samples [5] [6] [7] . A detailed description of the diagnostic technique has already been published 17 .
The patients studied in the initial phase (January to June 2006) were used as controls (control group) to assess the reliability of the technique. Physicians supervising treatment for these patients received conventional microbiological information, not the molecular diagnostic findings. once the reliability of the technique was confirmed, patients enrolled between July and December 2006 were included in the LCS group. In this group, however, the same supervising physicians were informed of the molecular diagnostic findings, so that initial antibiotic treatment could be adjusted adequately within the first few hours after detecting the clinical condition. Mortality during admission to hospital was used as the primary clinical impact measure of the LCS test, although our results showed that there was no difference in mortality between intervention and control groups. Consequently, we applied the rule that clinical decision-making should be based on the use of the less costly alternative and, therefore, the cost-minimisation of the test was assessed 18 .
Cost analysis
Cost-minimisation analysis is the type of costeffectiveness analysis applied when the benefit of both alternatives turns out to be equivalent 19 . Its purpose is to identify the least costly option. Cost calculations were based on the calculation of resources used in treatment and their unit costs. The study perspective was that of the hospital itself. The practical meaning of applying this approach is that only hospital-related costs were incorporated in the analysis 20 . The iCu and hospital length-of-stay after the diagnosis of septic shock and the antibiotics used were recorded for both patient groups for later conversion to cost per patient. The data were collected from hospital clinical records and databases. The hospital accounts department provided the resource unit costs. In order to estimate antibiotic cost, the antibiotics administered to each patient and the days of duration of each antibiotic treatment were recorded. Table 1 shows the unit values of the cost components per patient analysed. The calculation of the LCS test cost considered that the reagent kit costs €966 and allows for the analysis of seven patients. Processing the sample for one patient totalled €183, which included specific reagent cost (€138), personnel cost (€42.5) and imputable structural costs (€2.5 nursing minutes (€2.5) and six administrative minutes (€2).
Statistical analysis
The statistical significance of differences in costs between both groups was assessed by paired t-tests for the majority of the variables as they were normally distributed. When data were not normally distributed and for ordinal data, we used the non-parametric Wilcoxon signed-rank test. The significance level was set at P=0.05. Statistical analysis was carried out using SPSS software (version 19; SPSS Inc., Chicago, IL, USA).
An uncertainty analysis is advisable when conducting economic assessment studies. In this case it was considered necessary to estimate the probability that the use of the LCS technique would generate a net cost saving. To this effect, non-parametric bootstrapping was used with 1000 samples because the costs exhibited a non-normal distribution 21 .
Bootstrapping is a resampling method for assigning measures of accuracy to sample estimates. In this case, where a set of observations (total cost per patient) can be assumed to be from an independent and identically distributed population, this can be implemented by constructing a number of re-samples of the intervention and control datasets, each of which is obtained by random sampling with replacement from the original dataset 21 .
The sensitivity analysis involved modification of one parameter with observation of the changes in results 20 . Since sample processing is carried out in batches, there is a reasonable possibility that in real life, the technique must be applied under conditions in which the reagent cost per patient is not optimal. This happens when the number of patients is not a multiple of seven and particularly when the number is less than seven. The consequence is an increase in specific reagent cost per patient. A sensitivity analysis was carried out assuming a mean number of processed samples per batch of 3.5. This implied a unit cost per patient of €321.
rESULTS
The control and LCS groups consisted of 54 and 48 patients, respectively. Table 2 shows the demographic characteristics, initial diagnoses and origin of sepsis for both groups. no statistically significant differences were found in relation to the patient's age, gender or risk indices. The mortality rate after 28 days was 27% in the LCS group and 26% in the control group (Table 3) . The difference between the two groups was not statistically significant.
There was a significant difference (P <0.05) in iCu length-of-stay, which was 31.0±19.4 days in the control group and 22.9±29.9 days in the lCS group. Although the difference was not so marked, there was also a statistically significant difference between groups for mean stay in the hospital ward: 21.3±23.4 days in the control groups versus 18.3±21.4 days in the LCS group. The antibiotic costs showed important differences between the two groups, with a mean value of €2812 in the LCS group and €3576 in the control group. The total cost was greater in the control group (€42,198) than in the LCS group (€32,228), giving rise to an average net saving of €9970 per patient, mainly as a result of the differences in stay in the ICU.
Bootstrapping based on 1000 samples showed Polytrauma/head injuries 4 20 Heart surgery 20 2
Major vascular surgery 3 1
Pneumonectomy 1
lCS=lightCycler SeptiFast, Sd=standard deviation, nS=nonsignificant, CNS=central nervous system. real-time polymerase chain reaction microbiological diagnosis that in 963 cases, application of the LCS technique resulted in a negative cost increment (i.e. net cost saving), while in 37 cases a positive cost increment was recorded (Table 4 ). Thus, it can be concluded that the probability of cost saving by using the LCS technique in septic shock patients is 96.3%.
In the sensitivity analysis, the reduction in the number of sample processed per batch resulted in a mean cost increment with the LCS technique to €42,381, with a reduction in the mean difference of €183, thus giving rise to a final net saving of €9787 per patient. The probability of generating savings was 94.6% (Table 4) .
diSCuSSion
The main finding of the study was the significant economic saving afforded by the use of the LCS technique, due to the shortening of ICU stay and the use of fewer antibiotics. Given the clinical and economic relevance of severe sepsis and septic shock related to the frequent complications, high mortality and prolonged stay in the ICU and hospital ward 22 , microbiological tests allowing faster and more specific clinical decision-making which represented an important advance. Although the reduction of patient mortality is obviously the fundamental objective of any diagnostic or therapeutic technique applied to sepsis, cost reduction is also an important consideration. our assessment of the technique is positive, since the same efficacy is maintained with a marked reduction in antibiotic consumption and duration of ICU stay. The economic dimension of severe sepsis is very important, as reflected by the 450,000 cases treated in Europe each year and its estimated cost of €345 million in Spain alone 23 . Moreover, admission to the ICU intrinsically implies an added risk associated with pathogen exposure and the vulnerability that characterises patients with sepsis and septic shock. Consequently, a reduction of such exposure must be viewed as positive for patient prognosis.
As with other therapeutic measures such as haemodynamic stabilisation 24 , antibiotic use is considered mandatory in the treatment of severe sepsis and septic shock [14] [15] [16] . According to the current guidelines, antibiotics are to be provided on an early basis and, prior to their administration, cultures are required to establish microbiological diagnosis. The use of molecular techniques as an alternative to conventional diagnostic procedures, based on our capacity to isolate micro-organisms using appropriate culture media, is still far from becoming a reality. As recent literature shows, the speed and sensitivity of the LCS technique supports its use, but as a complement for blood culture, not as a substitute 11, 17, 25 .
The cost of antibiotics is important, however the bulk of economic saving is attributable to patient stay in the ICU and hospital. We have not found a rationale to explain the difference in length-of-stay, but patients of LSC group also show a tendency to need less catecholamines and fewer hours of mechanical ventilation but without statistical significance. The characteristics of patients in both groups were similar in terms of severity as measured by risk indices.
The causes of sepsis could have been an explanation if the distribution of diagnosis showed heterogeneity, but the differences were negligible. only the clinical application of LCS results to guide the antibiotics prescription differentiated the intervention group. decision-making criteria were the same in both groups and clinicians based the earlier discharge of patients from ICU in the LCS group on a more rapid clinical response to therapy. We did not register more drug side-effects due to broad-spectrum usage in the control group resulting in a longer ICU and hospital length-of-stay. The design of the study did not allow us to conclude that a causal relationship could be stated between lCS use and iCu length-ofstay, although we can maintain that this significant difference in length-of-stay is not random as both clinicians and patients' characteristics were the same. The only difference in the processes followed in both groups was the use of LCS results to decide antibiotic treatment.
The broad-spectrum treatment strategy often means that unnecessary antibiotics are administered and not suspended until the microbiological results are obtained. A reduction in the use of such antibiotics is important for economic reasons and, particularly, for medical reasons related to the iatrogenic effects of antibiotic treatment and the risk of generating resistance 26 . In our study, patients in the control group received an average of 5.1±3.1 antibiotics versus 4.2±2.2 in the lCS group (Table 3) , which represented a significant reduction in antibiotic use. Furthermore, not only were fewer antibiotics used, but their economic cost was also much lower in the LCS group (Table 3) .
The reduction and consequent rationalisation of antibiotic use is very important in planning and applying a quality antibiotic policy. our data suggest that this is facilitated by the combined use of these diagnostic techniques. As a result of the increase in resistance, the clinical efficacy of antibiotics (understood as their capacity to reach pharmacodynamic targets) in the ICU has decreased 27 . By adding genotypic diagnostics in the management of septic patients and reducing the number of antibiotics used, we can lessen the development of resistance without losing clinical efficacy.
The main limitation in this study is that mortality in both groups was similar after both 28 days and six months. Various authors have drawn attention to the relevance of early use of adequate antibiotics in septic patients [5] [6] [7] and to the increase in mortality seen in patients who are not adequately treated. identification of the causal micro-organism within a few hours should serve to improve the efficacy of antibiotic treatment, and thus improve patient survival, although we did not observe a reduction in mortality. This may be explained by a number of factors. First, it may reflect the size of our sample. Second, when severe sepsis or septic shock is suspected in any ICU, broad-spectrum treatment is started with very good possibilities of initial therapeutic success, though in many cases too many antibiotics are prescribed. Finally, the high mortality among such patients is determined not only by the infectious condition, but also by the background disease itself. Most of the subjects had undergone heart or abdominal surgery, or had suffered multiple injuries, with an intrinsically important risk of mortality that is not modified by the antibiotic treatment provided.
ConCluSionS
This study is the first report on the economic impact of using the LCS technique in clinical practice in patients with severe sepsis or septic shock. The main finding of the study was the significant economic savings afforded by using the LCS technique, due to shorter of length-of-stay in the iCu and less use of antibiotics. nevertheless, we did not find any advantage in terms of patient mortality. 
